Literature DB >> 17314232

Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.

Pimmada Jeamwattanalert1, Yuvadee Mahakunkijcharoen, Leera Kittigul, Pakpimol Mahannop, Sathit Pichyangkul, Chakrit Hirunpetcharat.   

Abstract

Merozoite surface protein 1 (MSP1) is the major protein on the surface of the plasmodial merozoite, and its carboxy terminus, the 19-kDa fragment (MSP1(19)), is highly conserved and effective in induction of a protective immune response against malaria parasite infection in mice and monkeys. However, the duration of the immune response has not been elucidated. As such, we immunized BALB/c mice with a standard four-dose injection of recombinant Plasmodium yoelii MSP1(19) formulated with Montanide ISA51 and CpG oligodeoxynucleotide (ODN) and monitored the MSP1(19)-specific antibody levels for up to 12 months. The antibody titers persisted constantly over the period of time without significant waning, in contrast to the antibody levels induced by immunization with Freund's adjuvant, where the antibody levels gradually declined to significantly lower levels 12 months after immunization. Investigation of immunoglobulin G (IgG) subclass longevity revealed that only the IgG1 antibody level (Th2 type-driven response) decreased significantly by 6 months, while the IgG2a antibody level (Th1 type-driven response) did not change over the 12 months after immunization, but the boosting effect was seen in the IgG1 antibody responses but not in the IgG2a antibody responses. After challenge infection, all immunized mice survived with negligibly patent parasitemia. These findings suggest that protective immune responses to MSP1(19) following immunization using oil-based Montanide ISA51 and CpG ODN as an adjuvant are very long-lasting and encourage clinical trials for malaria vaccine development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314232      PMCID: PMC1865617          DOI: 10.1128/CVI.00397-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  30 in total

1.  Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.

Authors:  C Hirunpetcharat; J H Tian; D C Kaslow; N van Rooijen; S Kumar; J A Berzofsky; L H Miller; M F Good
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

2.  Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.

Authors:  T Sparwasser; E S Koch; R M Vabulas; K Heeg; G B Lipford; J W Ellwart; H Wagner
Journal:  Eur J Immunol       Date:  1998-06       Impact factor: 5.532

3.  Plasmodium yoelii can ablate vaccine-induced long-term protection in mice.

Authors:  Michelle N Wykes; Yong-Hong Zhou; Xue Q Liu; Michael F Good
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

4.  Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.

Authors:  C Hirunpetcharat; P Vukovic; X Q Liu; D C Kaslow; L H Miller; M F Good
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

5.  The effects of DNA containing CpG motif on dendritic cells.

Authors:  S Behboudi; D Chao; P Klenerman; J Austyn
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

Review 6.  Vaccine-induced immunity to malaria parasites and the need for novel strategies.

Authors:  Michael F Good
Journal:  Trends Parasitol       Date:  2005-01

7.  CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.

Authors:  C L Cooper; H L Davis; M L Morris; S M Efler; M Al Adhami; A M Krieg; D W Cameron; J Heathcote
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.317

8.  Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model.

Authors:  H L Rotman; T M Daly; R Clynes; C A Long
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

9.  The global distribution of clinical episodes of Plasmodium falciparum malaria.

Authors:  Robert W Snow; Carlos A Guerra; Abdisalan M Noor; Hla Y Myint; Simon I Hay
Journal:  Nature       Date:  2005-03-10       Impact factor: 49.962

10.  Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP119) induces protective immunity to blood stage malaria infection in mice.

Authors:  C Hirunpetcharat; D Stanisic; X Q Liu; J Vadolas; R A Strugnell; R Lee; L H Miller; D C Kaslow; M F Good
Journal:  Parasite Immunol       Date:  1998-09       Impact factor: 2.280

View more
  7 in total

1.  Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.

Authors:  James R Alaro; Michele M Lynch; James M Burns
Journal:  Vaccine       Date:  2010-08-13       Impact factor: 3.641

2.  Immunization with the MAEBL M2 Domain Protects against Lethal Plasmodium yoelii Infection.

Authors:  Juliana A Leite; Daniel Y Bargieri; Bruna O Carvalho; Letusa Albrecht; Stefanie C P Lopes; Ana Carolina A V Kayano; Alessandro S Farias; Wan Ni Chia; Carla Claser; Benoit Malleret; Bruce Russell; Catarina Castiñeiras; Leonilda M B Santos; Marcelo Brocchi; Gerhard Wunderlich; Irene S Soares; Mauricio M Rodrigues; Laurent Rénia; Fabio T M Costa
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

3.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

4.  A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Authors:  James R Alaro; Andrea Partridge; Kazutoyo Miura; Ababacar Diouf; Ana M Lopez; Evelina Angov; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

5.  The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.

Authors:  Simone C de Cassan; Emily K Forbes; Alexander D Douglas; Anita Milicic; Bijender Singh; Puneet Gupta; Virander S Chauhan; Chetan E Chitnis; Sarah C Gilbert; Adrian V S Hill; Simon J Draper
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

6.  Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1.

Authors:  Feng Qian; Karine Reiter; Yanling Zhang; Richard L Shimp; Vu Nguyen; Joan A Aebig; Kelly M Rausch; Daming Zhu; Lynn Lambert; Gregory E D Mullen; Laura B Martin; Carole A Long; Louis H Miller; David L Narum
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

7.  Orientation of Antigen Display on Self-Assembling Protein Nanoparticles Influences Immunogenicity.

Authors:  Cosette G Schneider; Justin A Taylor; Michael Q Sibilo; Kazutoyo Miura; Katherine L Mallory; Christopher Mann; Christopher Karch; Zoltan Beck; Gary R Matyas; Carole A Long; Elke Bergmann-Leitner; Peter Burkhard; Evelina Angov
Journal:  Vaccines (Basel)       Date:  2021-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.